A Phase 1/2 interventional study of Systemic erythropoietin injection in Optic Atrophy, sponsored by Alexandria University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-07-13.
Sponsored by Alexandria University · Phase 1/2, Interventional, and Treatment
The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy.
The purpose of this treatment trial is to study the effect of systemic erythropoietin in patients having optic atrophy. The intervention is systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
Follow up after one month and three months by recording visual acuity and electro physiological studies.
16 studies on the registry are indexed under Optic Atrophy; 3 are open to participants now.
This study's enrollment of 10 is below the median of 23 across 10 interventional studies indexed under Optic Atrophy.
Browse Optic Atrophy studies →Alexandria University is the lead sponsor of 604 studies on the registry; 140 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study included 10 patients diagnosed as post papilledemic optic atrophy
Drug: Systemic erythropoietin injection
Systemic erythropoietin injections (eprax 10000 IU subcutaneous twice daily for three days).
Also known as: Eprax 10000
Visual acuity
VIsual acuity assessed at the follow up
Time frame: 3 months
Pattern visual evoked Potential .
Pattern visual evoked Potential .in both eyes to use data of the normal fellow eye as patients' internal control
Time frame: 3 months
Pattern electroretinogram
Pattern electroretinogram in both eyes to use data of the normal fellow eye as patients' internal control
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2020 to primary completion in Mar 2021, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.